person · Reporting owner

ESSIG STUART

Disclosed activity across 8 companies

Tapewire entity: 41994
SEC CIK: 0001187574

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ACCENDRA HEALTH INC/VA/OMI · Entity 6858	Director	June 28, 2019	July 02, 2019
DYNATRONICS CORPDYNT · Entity 73792	10% owner	October 30, 2025	October 30, 2025
IDEXX LABORATORIES INC /DEIDXX · Entity 3057	Director	May 12, 2026	May 14, 2026
INTEGRA LIFESCIENCES HOLDINGS CORPIART · Entity 2707	Director · President and CEO	June 01, 2026	June 03, 2026
Orthofix Medical Inc.OFIX · Entity 1975	Director	January 05, 2023	February 09, 2023
PIPER SANDLER COMPANIESPIPR · Entity 3863	Director	May 20, 2026	May 21, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACCENDRA HEALTH INC/VA/

Report date June 28, 2019 · Filed July 02, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom StockSEC Table II · derivative / convertible security	Direct	60,853	Reported balance After 2019-06-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-28 · Grant · Acquired 48 · Balance 60,853 F1: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F2: Shares acquired through quarterly dividend reinvestment transaction.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d).

F2: Shares acquired through quarterly dividend reinvestment transaction.

DYNATRONICS CORP

Report date October 30, 2025 · Filed October 30, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,533,824	Reported balance After 2025-10-30 transaction · row 1 1 source row Row 1 · 2025-10-30 · Other · Acquired 13,405 · Balance 4,533,824 F1: $0.0585 per share, payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. This form reflects additional shares to correct an underpayments reported on 10/1/25.
Common StockSEC Table I · non-derivative	IndirectFamily Trust	891,112	Reported balance After 2025-10-30 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-10-30 · Other · Acquired 2,690 · Balance 891,112 F1: $0.0585 per share, payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. This form reflects additional shares to correct an underpayments reported on 10/1/25.

Filing footnotes · ownership attribution and instrument terms

F1: $0.0585 per share, payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. This form reflects additional shares to correct an underpayments reported on 10/1/25.

IDEXX LABORATORIES INC /DE

Report date May 12, 2026 · Filed May 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $533.92 · Expires 2036-05-11	Direct	525	Reported balance After 2026-05-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-12 · Grant · Acquired 525 · Balance 525 F1: Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	234	Reported balance After 2026-05-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-12 · Grant · Acquired 234 · Balance 234 F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.

Filing footnotes · ownership attribution and instrument terms

F1: Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.

F2: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.

INTEGRA LIFESCIENCES HOLDINGS CORP

Report date June 01, 2026 · Filed June 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.67 · Expires 2034-06-01	Direct	705,468	Reported balance After 2026-06-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-01 · Grant · Acquired 705,468 · Balance 705,468 F1: This award consists of (x) 482,976 stock options granted pursuant to the equity award provisions of the Reporting Person's employment agreement with the Issuer (the "Employment Agreement"), and (y) 222,492 stock options granted at the discretion of the Compensation Committee of the Issuer's Board of Directors (the "Compensation Committee"). All stock options reported in this row were granted under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan") and will vest as to one-third of such stock options on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	365,297	Reported balance After 2026-06-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-01 · Grant · Acquired 365,297 · Balance 365,297 F2: Grant of restricted stock units ("RSUs") pursuant to the Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3: This award consists of (x) 255,265 RSUs granted pursuant to the equity award provisions of the Employment Agreement, and (y) 110,032 RSUs granted at the discretion of the Compensation Committee. All RSUs reported in this row were granted under the Plan and will vest as to one-third of the shares on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates.

Filing footnotes · ownership attribution and instrument terms

F1: This award consists of (x) 482,976 stock options granted pursuant to the equity award provisions of the Reporting Person's employment agreement with the Issuer (the "Employment Agreement"), and (y) 222,492 stock options granted at the discretion of the Compensation Committee of the Issuer's Board of Directors (the "Compensation Committee"). All stock options reported in this row were granted under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the "Plan") and will vest as to one-third of such stock options on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates.

F2: Grant of restricted stock units ("RSUs") pursuant to the Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F3: This award consists of (x) 255,265 RSUs granted pursuant to the equity award provisions of the Employment Agreement, and (y) 110,032 RSUs granted at the discretion of the Compensation Committee. All RSUs reported in this row were granted under the Plan and will vest as to one-third of the shares on the first anniversary of 5/1/2026 and thereafter in monthly installments through the following twenty-four months, in each case subject to the Reporting Person's continued service through the applicable vesting dates.

Orthofix Medical Inc.

Report date January 05, 2023 · Filed February 09, 2023 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	205,966	Reported balance After 2023-01-05 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2023-01-05 · Grant · Acquired 14,354 · Balance 205,966 F1: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vests in full on the earlier of (i) June 30, 2024 or (ii) the date that the Company holds its 2024 annual meeting of stockholders. F2: This amendment is being made to correct the vesting date and the number of Deferred Stock Units awarded to the reporting person on January 5, 2023. F3: Includes 14,354 deferred stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vests in full on the earlier of (i) June 30, 2024 or (ii) the date that the Company holds its 2024 annual meeting of stockholders.

F2: This amendment is being made to correct the vesting date and the number of Deferred Stock Units awarded to the reporting person on January 5, 2023.

F3: Includes 14,354 deferred stock units.

PIPER SANDLER COMPANIES

Report date May 20, 2026 · Filed May 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,575	Reported balance After 2026-05-20 transaction · row 1 1 source row Row 1 · 2026-05-20 · Grant · Acquired 1,875 · Balance 2,575

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ST JUDE MEDICAL, LLC

Report date January 04, 2017 · Filed January 06, 2017

Section 16 reporting ended · disclosed 2017-01-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-01-04 transaction · row 1 1 source row Row 1 · 2017-01-04 · Disposition to issuer · Disposed 48,777 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.45 · Expires 2017-05-08	Direct	Reported balance After 2017-01-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-01-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.45 · Expires 2017-05-08	Direct	Reported balance After 2017-01-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-01-04 · Disposition to issuer · Disposed 2,250 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.15 · Expires 2018-05-07	Direct	Reported balance After 2017-01-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-01-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.15 · Expires 2018-05-07	Direct	Reported balance After 2017-01-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-01-04 · Disposition to issuer · Disposed 600 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.17 · Expires 2019-05-12	Direct	Reported balance After 2017-01-04 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-01-04 · Disposition to issuer · Disposed 9,700 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.51 · Expires 2020-05-03	Direct	Reported balance After 2017-01-04 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-01-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.51 · Expires 2020-05-03	Direct	Reported balance After 2017-01-04 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-01-04 · Disposition to issuer · Disposed 5,400 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.

F2: Pursuant to the Merger Agreement, each option that was fully vested and exercisable immediately prior to the mergers contemplated by the Merger Agreement (the "Mergers"), was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) shares of Issuer Common Stock with a Fair Market Value equal to the aggregate exercise price of such option. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.

SeaSpine Holdings Corp

Report date January 05, 2023 · Filed January 10, 2023

Section 16 reporting ended · disclosed 2023-01-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-01-05 transaction · row 1 1 source row Row 1 · 2023-01-05 · Disposition to issuer · Disposed 460,275 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, SeaSpine Holdings Corporation, which became effective on January 5, 2023, in exchange for 191,612 Orthofix Medical Inc. ("Orthofix") ordinary shares having a market value of $22.76 per share at the effective time of the merger.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.68 · Expires 2025-08-01	Direct	Reported balance After 2023-01-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-01-05 · Disposition to issuer · Disposed 98,198 · Balance 0 F3: This option was assumed by Orthofix in the merger and replaced with an option to purchase 40,879 shares of Orthofix at a price of $37.67 per share. F2: The option vests as to 25% of the underlying shares on November 1, 2015 and the remaining 75% in three equal quarterly installments thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.18 · Expires 2026-01-01	Direct	Reported balance After 2023-01-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-01-05 · Disposition to issuer · Disposed 6,944 · Balance 0 F5: This option was assumed by Orthofix in the merger and replaced with an option to purchase 2,890 shares of Orthofix at a price of $41.27 per share. F4: The option vests as to 50% of the underlying shares on February 1, 2016 and as to 25% of the underlying shares on each of May 1, 2016 and August 1, 2016.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.99 · Expires 2026-06-07	Direct	Reported balance After 2023-01-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-01-05 · Disposition to issuer · Disposed 25,056 · Balance 0 F7: This option was assumed by Orthofix in the merger and replaced with an option to purchase 10,430 shares of Orthofix at a price of $24.00 per share. F6: The option vests in four equal installments on each of September 7, 2016, December 7, 2016, March 7, 2017 and June 7, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, SeaSpine Holdings Corporation, which became effective on January 5, 2023, in exchange for 191,612 Orthofix Medical Inc. ("Orthofix") ordinary shares having a market value of $22.76 per share at the effective time of the merger.

F2: The option vests as to 25% of the underlying shares on November 1, 2015 and the remaining 75% in three equal quarterly installments thereafter.

F3: This option was assumed by Orthofix in the merger and replaced with an option to purchase 40,879 shares of Orthofix at a price of $37.67 per share.

F4: The option vests as to 50% of the underlying shares on February 1, 2016 and as to 25% of the underlying shares on each of May 1, 2016 and August 1, 2016.

F5: This option was assumed by Orthofix in the merger and replaced with an option to purchase 2,890 shares of Orthofix at a price of $41.27 per share.

F6: The option vests in four equal installments on each of September 7, 2016, December 7, 2016, March 7, 2017 and June 7, 2017.

F7: This option was assumed by Orthofix in the merger and replaced with an option to purchase 10,430 shares of Orthofix at a price of $24.00 per share.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 17, 2023 Filed May 19, 2023 21:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantNon-Qualified Stock Option (right-to-buy) · Derivative	645	$0.00 Strike: $487.12	$0.00	Disclosure SEC source: 0000874716-23-000078 · wf-form4_168453009809122.xml · derivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 645 Underlying: Common Stock · 645 shares Expires 2033-05-16 F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. Read SEC document
May 12, 2023 Filed May 16, 2023 20:11 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	5,505	$0.00	$0.00	Disclosure SEC source: 0001209191-23-029773 · doc4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,152,329 Read SEC document
May 11, 2023 Filed May 15, 2023 21:31 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	344	Not disclosed	Not disclosed	Disclosure SEC source: 0000874716-23-000054 · wf-form4_168418629068677.xml · derivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 344 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier. F2 · price: Not applicable. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier. Read SEC document
May 11, 2023 Filed May 15, 2023 21:31 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	344	$0.00	$0.00	Disclosure SEC source: 0000874716-23-000054 · wf-form4_168418629068677.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 05, 2023 Filed Apr 7, 2023 16:57 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	8,123	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-23-008939 · form4.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Family Trust Disclosed balance after: 93,698 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
April 05, 2023 Filed Apr 7, 2023 16:57 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	40,469	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-23-008939 · form4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 464,782 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
January 05, 2023 Filed Jan 10, 2023 00:01 UTC	Orthofix Medical Inc. OFIX · Entity 1975	GrantCommon Stock	14,052	$0.00	$0.00	Disclosure SEC source: 0001209191-23-002652 · doc4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,664 F1 · shares: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vests in full on the first anniversary of the grant date, January 5, 2023. F2 · balance_after: Includes 14,052 deferred stock units. Read SEC document
January 05, 2023 Filed Jan 10, 2023 00:18 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	Disposition to issuerStock Option (right to buy) · Derivative	25,056	Not disclosed Strike: $9.99	Not disclosed	Disclosure SEC source: 0001637761-23-000039 · wf-form4_167330992488845.xml · derivative · entry 4 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,056 shares Expires 2026-06-07 F7 · price: This option was assumed by Orthofix in the merger and replaced with an option to purchase 10,430 shares of Orthofix at a price of $24.00 per share. F6 · derivative.exercise_date: The option vests in four equal installments on each of September 7, 2016, December 7, 2016, March 7, 2017 and June 7, 2017. Read SEC document
January 05, 2023 Filed Jan 10, 2023 00:18 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	Disposition to issuerStock Option (right to buy) · Derivative	6,944	Not disclosed Strike: $17.18	Not disclosed	Disclosure SEC source: 0001637761-23-000039 · wf-form4_167330992488845.xml · derivative · entry 3 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,944 shares Expires 2026-01-01 F5 · price: This option was assumed by Orthofix in the merger and replaced with an option to purchase 2,890 shares of Orthofix at a price of $41.27 per share. F4 · derivative.exercise_date: The option vests as to 50% of the underlying shares on February 1, 2016 and as to 25% of the underlying shares on each of May 1, 2016 and August 1, 2016. Read SEC document
January 05, 2023 Filed Jan 10, 2023 00:18 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	Disposition to issuerStock Option (right to buy) · Derivative	98,198	Not disclosed Strike: $15.68	Not disclosed	Disclosure SEC source: 0001637761-23-000039 · wf-form4_167330992488845.xml · derivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 98,198 shares Expires 2025-08-01 F3 · price: This option was assumed by Orthofix in the merger and replaced with an option to purchase 40,879 shares of Orthofix at a price of $37.67 per share. F2 · derivative.exercise_date: The option vests as to 25% of the underlying shares on November 1, 2015 and the remaining 75% in three equal quarterly installments thereafter. Read SEC document
January 05, 2023 Filed Jan 10, 2023 00:18 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	Disposition to issuerCommon Stock	460,275	Not disclosed	Not disclosed	Disclosure SEC source: 0001637761-23-000039 · wf-form4_167330992488845.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, SeaSpine Holdings Corporation, which became effective on January 5, 2023, in exchange for 191,612 Orthofix Medical Inc. ("Orthofix") ordinary shares having a market value of $22.76 per share at the effective time of the merger. Read SEC document
January 05, 2023 Filed Jan 11, 2023 21:51 UTC	DYNATRONICS CORP DYNT · Entity 73792	GrantCommon Stock	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-23-000315 · section16.xml · nonDerivative · entry 3 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Spouse Disclosed balance after: 115,601 F2 · price: Shares issues as compensation for services as a director of the Issuer, valued at $1.00 Read SEC document
January 05, 2023 Filed Jan 11, 2023 21:51 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	30,302	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-23-000315 · section16.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 312,276 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
January 05, 2023 Filed Jan 11, 2023 21:51 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	150,978	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-23-000315 · section16.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,121,566 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
January 05, 2023 Filed Feb 9, 2023 22:55 UTC Amendment	Orthofix Medical Inc. OFIX · Entity 1975	GrantCommon Stock	14,354	$0.00	$0.00	Disclosure SEC source: 0001209191-23-008126 · doc4a.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,966 F1 · shares: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vests in full on the earlier of (i) June 30, 2024 or (ii) the date that the Company holds its 2024 annual meeting of stockholders. F2 · shares: This amendment is being made to correct the vesting date and the number of Deferred Stock Units awarded to the reporting person on January 5, 2023. F3 · balance_after: Includes 14,354 deferred stock units. Read SEC document
October 31, 2022 Filed Jan 31, 2023 21:11 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GiftCommon Stock	159,012	$0.00	$0.00	Disclosure SEC source: 0001209191-23-005679 · doc5.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By GRAT III Disclosed balance after: 0 F1 · balance_after: In accordance with the provisions of the Grantor Annuity Trust, 159,012 shares of the Issuer's common stock were transferred from the GRAT to the Stuart M. Essig 2010 Remainder Trust upon termination of the GRAT. Read SEC document
October 04, 2022 Filed Oct 5, 2022 15:16 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	23,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-22-013395 · section16.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 281,974 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
October 04, 2022 Filed Oct 5, 2022 15:16 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	117,085	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-22-013395 · section16.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,970,588 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
July 07, 2022 Filed Jul 12, 2022 08:02 UTC	DYNATRONICS CORP DYNT · Entity 73792	GrantCommon Stock	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-22-009552 · section16.xml · nonDerivative · entry 3 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Spouse Disclosed balance after: 110,601 F2 · price: Shares issues as compensation for services as a director of the Issuer, valued at $0.61 Read SEC document
July 07, 2022 Filed Jul 12, 2022 08:02 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	20,376	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-22-009552 · section16.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 258,474 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
July 07, 2022 Filed Jul 12, 2022 08:02 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	101,520	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-22-009552 · section16.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,853,503 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
June 01, 2022 Filed Jun 3, 2022 21:23 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	GrantCommon Stock	15,943	$0.00	$0.00	Disclosure SEC source: 0001637761-22-000093 · wf-form4_165429137463047.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,275 F1 · shares: The restricted stock award vests in full on June 1, 2023, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. Read SEC document
May 13, 2022 Filed May 17, 2022 20:41 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	4,215	$0.00	$0.00	Disclosure SEC source: 0001209191-22-029701 · doc4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,146,824 F1 · balance_after: In accordance with the provisions of his Grantor Retained Annuity Trust, 240,988 shares were distributed from the GRAT to the reporting person. Read SEC document
May 11, 2022 Filed May 13, 2022 21:56 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	224	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-22-010578 · doc1.xml · derivative · entry 4 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344 Underlying: Common Stock · 224 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier. F4 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier. Read SEC document
May 11, 2022 Filed May 13, 2022 21:56 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantRestricted Stock Unit · Derivative	344	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-22-010578 · doc1.xml · derivative · entry 3 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568 Underlying: Common Stock · 344 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier. F4 · price: Not applicable. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier. Read SEC document
May 11, 2022 Filed May 13, 2022 21:56 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantNon-Qualified Stock Option (right-to-buy) · Derivative	945	Not disclosed Strike: $333.90	Not disclosed	Disclosure SEC source: 0001567619-22-010578 · doc1.xml · derivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 945 Underlying: Common Stock · 945 shares Expires 2032-05-10 F4 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier. Read SEC document
May 11, 2022 Filed May 13, 2022 21:56 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	224	$0.00	$0.00	Disclosure SEC source: 0001567619-22-010578 · doc1.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 04, 2022 Filed Apr 5, 2022 08:01 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	17,089	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-22-004581 · section16.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 238,098 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
April 04, 2022 Filed Apr 5, 2022 08:01 UTC	DYNATRONICS CORP DYNT · Entity 73792	OtherCommon Stock	85,143	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-22-004581 · section16.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,751,983 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
January 28, 2022 Filed Feb 1, 2022 22:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantCommon Stock	49	$489.05	$23,963.45	Disclosure SEC source: 0001567619-22-002286 · doc1.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,149 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($23,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document
January 04, 2022 Filed Jan 5, 2022 09:14 UTC	DYNATRONICS CORP DYNT · Entity 73792	PurchaseCommon Stock	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-22-000209 · section16.xml · nonDerivative · entry 3 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Spouse Disclosed balance after: 105,601 F2 · price: Shares issues as compensation for services as a director of the Issuer, valued at $1.00. Read SEC document
January 04, 2022 Filed Jan 5, 2022 09:14 UTC	DYNATRONICS CORP DYNT · Entity 73792	PurchaseCommon Stock	12,561	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-22-000209 · section16.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 221,009 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
January 04, 2022 Filed Jan 5, 2022 09:14 UTC	DYNATRONICS CORP DYNT · Entity 73792	PurchaseCommon Stock	62,585	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-22-000209 · section16.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,666,840 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
October 29, 2021 Filed Nov 2, 2021 21:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantCommon Stock	36	$666.14	$23,981.04	Disclosure SEC source: 0001567619-21-019215 · doc1.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($23,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document
October 04, 2021 Filed Oct 5, 2021 16:25 UTC	DYNATRONICS CORP DYNT · Entity 73792	PurchaseCommon stock	8,749	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-21-010825 · section16.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Family trust Disclosed balance after: 208,448 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
October 04, 2021 Filed Oct 5, 2021 16:25 UTC	DYNATRONICS CORP DYNT · Entity 73792	PurchaseCommon stock	43,589	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-21-010825 · section16.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,604,255 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
July 30, 2021 Filed Aug 3, 2021 21:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantCommon Stock	35	$678.53	$23,748.55	Disclosure SEC source: 0001567619-21-014355 · doc1.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,064 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($23,750.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document
July 06, 2021 Filed Jul 12, 2021 12:39 UTC	DYNATRONICS CORP DYNT · Entity 73792	PurchaseCommon Stock	5,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-21-007804 · section16.xml · nonDerivative · entry 3 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Spouse Disclosed balance after: 100,601 F2 · price: Shares issues as compensation for services as a director of the Issuer, valued at $1.20. Read SEC document
July 06, 2021 Filed Jul 12, 2021 12:39 UTC	DYNATRONICS CORP DYNT · Entity 73792	PurchaseCommon Stock	10,558	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-21-007804 · section16.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 199,699 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
July 06, 2021 Filed Jul 12, 2021 12:39 UTC	DYNATRONICS CORP DYNT · Entity 73792	PurchaseCommon Stock	52,604	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-21-007804 · section16.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,560,666 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
June 30, 2021 Filed Jul 2, 2021 23:07 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	GrantCommon Stock	1,097	$0.00	$0.00	Disclosure SEC source: 0001637761-21-000148 · wf-form4_162526720884570.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,332 F1 · shares: This restricted stock award was issued to the Reporting Person pursuant to his election under the issuer's director compensation program to receive such award in lieu of a portion of the cash retainer the Reporting Person is entitled to receive in his capacity as a non-employee director of the issuer. The restricted stock award vests immediately on the date of grant. The number of shares was calculated by dividing the portion of the retainer the Reporting Person elected not to receive in cash by the closing price of the issuer's common stock on the last trading day of the quarter. Read SEC document
June 02, 2021 Filed Jun 4, 2021 20:15 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	GrantCommon Stock	6,253	$0.00	$0.00	Disclosure SEC source: 0001637761-21-000127 · wf-form4_162283770841964.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,235 F1 · shares: The restricted stock award vests in full on June 2, 2022, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation ("SeaSpine") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. Read SEC document
May 14, 2021 Filed May 17, 2021 20:09 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	GrantCommon Stock	3,532	$0.00	$0.00	Disclosure SEC source: 0001209191-21-033126 · doc4.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,621 Read SEC document
May 12, 2021 Filed May 14, 2021 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantNon-Qualified Stock Option (right-to-buy) · Derivative	723	Not disclosed Strike: $512.31	Not disclosed	Disclosure SEC source: 0001567619-21-010253 · doc1.xml · derivative · entry 2 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723 Underlying: Common Stock · 723 shares Expires 2031-05-11 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier. Read SEC document
May 12, 2021 Filed May 14, 2021 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantRestricted Stock Unit · Derivative	224	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-21-010253 · doc1.xml · derivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224 Underlying: Common Stock · 224 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier. F3 · price: Not applicable. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier. Read SEC document
April 30, 2021 Filed May 4, 2021 23:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantCommon Stock	36	$548.99	$19,763.64	Disclosure SEC source: 0001567619-21-009016 · doc1.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,029 F1 · shares: Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the "Plan") in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($20,000.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock one year following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan. Read SEC document
April 05, 2021 Filed Apr 6, 2021 17:22 UTC	DYNATRONICS CORP DYNT · Entity 73792	PurchaseCommon Stock	10,893	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-21-003906 · section16.xml · nonDerivative · entry 2 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 189,141 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
April 05, 2021 Filed Apr 6, 2021 17:22 UTC	DYNATRONICS CORP DYNT · Entity 73792	PurchaseCommon Stock	54,271	Not disclosed	Not disclosed	Disclosure SEC source: 0001654954-21-003906 · section16.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,508,062 F1 · price: Payment of quarterly dividends on 8% Preferred Stock in shares of common stock valued at 90% of 10-day average closing bid price. Read SEC document
March 31, 2021 Filed Apr 1, 2021 23:25 UTC	SeaSpine Holdings Corp SPNE · Entity 120832	GrantCommon Stock	1,293	$0.00	$0.00	Disclosure SEC source: 0001637761-21-000071 · wf-form4_161731944550267.xml · nonDerivative · entry 1 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,982 F1 · shares: This restricted stock award was issued to the Reporting Person pursuant to his election under the issuer's director compensation program to receive such award in lieu of a portion of the cash retainer the Reporting Person is entitled to receive in his capacity as a non-employee director of the issuer. The restricted stock award vests immediately on the date of grant. The number of shares was calculated by dividing the portion of the retainer the Reporting Person elected not to receive in cash by the closing price of the issuer's common stock on the last trading day of the quarter. Read SEC document
March 18, 2021 Filed Mar 22, 2021 20:13 UTC	INTEGRA LIFESCIENCES HOLDINGS CORP IART · Entity 2707	SaleCommon Stock	214,553	$68.14	$14,619,641.42	Disclosure SEC source: 0001209191-21-022327 · doc4.xml · nonDerivative · entry 4 ESSIG STUART · CIK 0001187574 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F3 · kind: The Trust contributed Issuer common stock to an exchange fund in exchange for shares of the exchange fund. The Issuer common stock was valued at $68.14 per share for the purpose of determining the number of shares of the exchange fund issuable to the Trust. F3 · price: The Trust contributed Issuer common stock to an exchange fund in exchange for shares of the exchange fund. The Issuer common stock was valued at $68.14 per share for the purpose of determining the number of shares of the exchange fund issuable to the Trust. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.